Whether the effects of meticrane led to the alteration in cell viability and proliferation in leukemia cells (K562 and Jurkat) and liver cancer cells (SK-hep-1) can be enhanced with known epigenetic inhibitors, we assayed both the DNMT1 inhibitor (5AC) and HDAC inhibitor (CUDC-101) in these cells for 72 h using CCK8 assay (Figures 2A, B). The gene discussed is DNMT1; the disease is leukemia.